Pectolinarigenin regulates the tumor-associated proteins in AGS-xenograft BALB/c nude mice.
AGS-xenograft
PI3K/AKT/mTOR
Pectolinarigenin
Proteomics
Tumor suppress
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
16 Feb 2024
16 Feb 2024
Historique:
received:
07
03
2023
accepted:
30
10
2023
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
16
2
2024
Statut:
epublish
Résumé
Pectolinarigenin (PEC) is a flavone extracted from Cirsium, and because it has anti-inflammatory properties, anti-cancer research is also being conducted. The objective of this work was to find out if PEC is involved in tumor control and which pathways it regulates in vivo and in vitro. AGS cell lines were xenografted into BALB/c nude mice to create tumors, and PEC was administered intraperitoneally to see if it was involved in tumor control. Once animal testing was completed, tumor proteins were isolated and identified using LC-MS analysis, and gene ontology of the found proteins was performed. Body weight and hematological measurements on the xenograft mice model demonstrated that PEC was not harmful to non-cancerous cells. We found 582 proteins in tumor tissue linked to biological reactions such as carcinogenesis and cell death signaling. PEC regulated 6 out of 582 proteins in vivo and in vitro in the same way. Our findings suggested that PEC therapy may inhibit tumor development in gastric cancer (GC), and proteomic research gives fundamental information about proteins that may have great promise as new therapeutic targets in GC.
Sections du résumé
BACKGROUND
BACKGROUND
Pectolinarigenin (PEC) is a flavone extracted from Cirsium, and because it has anti-inflammatory properties, anti-cancer research is also being conducted. The objective of this work was to find out if PEC is involved in tumor control and which pathways it regulates in vivo and in vitro.
METHODS
METHODS
AGS cell lines were xenografted into BALB/c nude mice to create tumors, and PEC was administered intraperitoneally to see if it was involved in tumor control. Once animal testing was completed, tumor proteins were isolated and identified using LC-MS analysis, and gene ontology of the found proteins was performed.
RESULTS
RESULTS
Body weight and hematological measurements on the xenograft mice model demonstrated that PEC was not harmful to non-cancerous cells. We found 582 proteins in tumor tissue linked to biological reactions such as carcinogenesis and cell death signaling. PEC regulated 6 out of 582 proteins in vivo and in vitro in the same way.
CONCLUSION
CONCLUSIONS
Our findings suggested that PEC therapy may inhibit tumor development in gastric cancer (GC), and proteomic research gives fundamental information about proteins that may have great promise as new therapeutic targets in GC.
Identifiants
pubmed: 38361124
doi: 10.1007/s11033-023-09046-4
pii: 10.1007/s11033-023-09046-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
305Subventions
Organisme : National Research Foundation of Korea
ID : 2020R1F1A1074115
Organisme : National Research Foundation of Korea
ID : NRF-2022R1F1A1069365
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
Sekiguchi M, Oda I, Matsuda T, Saito Y (2021) Epidemiological trends and future perspectives of gastric cancer in Eastern Asia. Digestion. https://doi.org/10.1159/000518483
doi: 10.1159/000518483
pubmed: 34551417
Jung KW, Won YJ, Kong HJ, Lee ES (2019) Prediction of cancer incidence and mortality in Korea, 2019. Cancer Res Treat 51(2):431–437. https://doi.org/10.4143/crt.2019.139
doi: 10.4143/crt.2019.139
pubmed: 30913864
pmcid: 6473283
Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP (2018) Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manage Res 10:239–248. https://doi.org/10.2147/CMAR.S149619
doi: 10.2147/CMAR.S149619
Rawla P, Barsouk A (2019) Epidemiology of gastric cancer: global trends, risk factors and prevention. Przeglad Gastroenterol 14(1):26–38. https://doi.org/10.5114/pg.2018.80001
doi: 10.5114/pg.2018.80001
Ponte LGS, Pavan ICB, Mancini MCS, da Silva LGS, Morelli AP, Severino MB et al (2021) The Hallmarks of flavonoids in cancer. Molecules 26(7):2029. https://doi.org/10.3390/molecules26072029
doi: 10.3390/molecules26072029
pubmed: 33918290
pmcid: 8038160
Shen N, Wang T, Gan Q, Liu S, Wang L, Jin B (2022) Plant flavonoids: classification, distribution, biosynthesis, and antioxidant activity. Food Chem 383:132531. https://doi.org/10.1016/j.foodchem.2022.132531
doi: 10.1016/j.foodchem.2022.132531
pubmed: 35413752
Vezza T, Rodriguez-Nogales A, Algieri F, Utrilla MP, Rodriguez-Cabezas ME, Galvez J (2016) Flavonoids in inflammatory bowel disease: a review. Nutrients 8(4):211. https://doi.org/10.3390/nu8040211
doi: 10.3390/nu8040211
pubmed: 27070642
pmcid: 4848680
Ciumarnean L, Milaciu MV, Runcan O, Vesa SC, Rachisan AL, Negrean V et al (2020) The effects of flavonoids in cardiovascular diseases. Molecules. https://doi.org/10.3390/molecules25184320
doi: 10.3390/molecules25184320
pubmed: 32967119
pmcid: 7571023
Al-Ishaq RK, Overy AJ, Busselberg D (2020) Phytochemicals and gastrointestinal cancer: cellular mechanisms and effects to change cancer progression. Biomolecules 10(1):105. https://doi.org/10.3390/biom10010105
doi: 10.3390/biom10010105
pubmed: 31936288
pmcid: 7022462
Lee HJ, Nagappan A, Park HS, Hong GE, Yumnam S, Raha S et al (2015) Flavonoids isolated from Citrus platymamma induce mitochondrial-dependent apoptosis in AGS cells by modulation of the PI3K/AKT and MAPK pathways. Oncol Rep 34(3):1517–1525. https://doi.org/10.3892/or.2015.4122
doi: 10.3892/or.2015.4122
pubmed: 26165353
Lim H, Son KH, Chang HW, Bae K, Kang SS, Kim HP (2008) Anti-inflammatory activity of pectolinarigenin and pectolinarin isolated from Cirsium Chanroenicum. Biol Pharm Bull 31(11):2063–2067. https://doi.org/10.1248/bpb.31.2063
doi: 10.1248/bpb.31.2063
pubmed: 18981574
Yoo YM, Nam JH, Kim MY, Choi J, Park HJ (2008) Pectolinarin and pectolinarigenin of Cirsium setidens prevent the hepatic injury in rats caused by D-galactosamine via an antioxidant mechanism. Biol Pharm Bull 31(4):760–764. https://doi.org/10.1248/bpb.31.760
doi: 10.1248/bpb.31.760
pubmed: 18379079
Wang C, Cheng Y, Liu H, Xu Y, Peng H, Lang J et al (2016) Pectolinarigenin suppresses the tumor growth in nasopharyngeal carcinoma. Cellular Physiol Biochem Int J Exp Cellular Physiol Biochem Pharmacol 39(5):1795–1803. https://doi.org/10.1159/000447879
doi: 10.1159/000447879
Lee HJ, Venkatarame Gowda Saralamma V, Kim SM, Ha SE, Raha S, Lee WS et al (2018) Pectolinarigenin induced cell cycle arrest, autophagy, and apoptosis in gastric cancer cell via PI3K/AKT/mTOR signaling pathway. Nutrients. https://doi.org/10.3390/nu10081043
doi: 10.3390/nu10081043
pubmed: 30597920
pmcid: 6357030
Lee HJ, Venkatarame Gowda Saralamma V, Kim SM, Ha SE, Vetrivel P, Kim EH et al (2018) Comparative proteomic profiling of tumor-associated proteins in human gastric cancer cells treated with pectolinarigenin. Nutrients 10(11):1596. https://doi.org/10.3390/nu10111596
doi: 10.3390/nu10111596
pubmed: 30380781
pmcid: 6265996
Srinivas PR, Verma M, Zhao Y, Srivastava S (2002) Proteomics for cancer biomarker discovery. Clin Chem 48(8):1160–1169
pubmed: 12142368
Cho WC (2007) Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 6:25. https://doi.org/10.1186/1476-4598-6-25
doi: 10.1186/1476-4598-6-25
pubmed: 17407558
pmcid: 1852117
He QY, Chiu JF (2003) Proteomics in biomarker discovery and drug development. J Cell Biochem 89(5):868–886. https://doi.org/10.1002/jcb.10576
doi: 10.1002/jcb.10576
pubmed: 12874822
Jain KK (2002) Proteomics-based anticancer drug discovery and development. Technol Cancer Res Treat 1(4):231–236. https://doi.org/10.1177/153303460200100403
doi: 10.1177/153303460200100403
pubmed: 12625781
Fernandes DP, Pimentel MML, Santos FAD, Praxedes EA, Brito PD, Lima MA et al (2018) Hematological and biochemical profile of BALB/c nude and C57BL/6 SCID female mice after ovarian xenograft. Anais Da Academia Brasileira De Ciencias 90(4):3941–3948. https://doi.org/10.1590/0001-3765201820180586
doi: 10.1590/0001-3765201820180586
pubmed: 30379274
Silva-Santana G, Bax JC, Fernandes DCS, Bacellar DTL, Hooper C, Dias A et al (2020) Clinical hematological and biochemical parameters in Swiss, BALB/c, C57BL/6 and B6D2F1 Mus musculus. Anim Models Exp Med 3(4):304–315. https://doi.org/10.1002/ame2.12139
doi: 10.1002/ame2.12139
Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497–5510. https://doi.org/10.1038/onc.2008.245
doi: 10.1038/onc.2008.245
pubmed: 18794884
pmcid: 3398461
Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16(8):797–803. https://doi.org/10.1097/01.cad.0000173476.67239.3b
doi: 10.1097/01.cad.0000173476.67239.3b
pubmed: 16096426
Zeng Q, Ou L, Wang W, Guo DY, Gastrin (2020) Cholecystokinin, signaling, and biological activities in cellular processes. Front Endocrinol 11:112. https://doi.org/10.3389/fendo.2020.00112
doi: 10.3389/fendo.2020.00112
Okada N, Kubota A, Imamura T, Suwa H, Kawaguchi Y, Ohshio G et al (1996) Evaluation of cholecystokinin, gastrin, CCK-A receptor, and CCK-B/gastrin receptor gene expressions in gastric cancer. Cancer Lett 106(2):257–262. https://doi.org/10.1016/0304-3835(96)04325-x
doi: 10.1016/0304-3835(96)04325-x
pubmed: 8844981
Rai R, Chandra V, Tewari M, Kumar M, Shukla HS (2012) Cholecystokinin and gastrin receptors targeting in gastrointestinal cancer. Surg Oncol 21(4):281–292. https://doi.org/10.1016/j.suronc.2012.06.004
doi: 10.1016/j.suronc.2012.06.004
pubmed: 22801592
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X et al (2016) Ferroptosis: process and function. Cell Death Differ 23(3):369–379. https://doi.org/10.1038/cdd.2015.158
doi: 10.1038/cdd.2015.158
pubmed: 26794443
pmcid: 5072448
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
doi: 10.1016/j.cell.2012.03.042
pubmed: 22632970
pmcid: 3367386
Wang J, Guo C, Liu S, Qi H, Yin Y, Liang R et al (2014) Annexin A11 in disease. Clin Chim Acta 431:164–168. https://doi.org/10.1016/j.cca.2014.01.031
doi: 10.1016/j.cca.2014.01.031
pubmed: 24508622
Hua K, Li Y, Zhao Q, Fan L, Tan B, Gu J (2018) Downregulation of annexin A11 (ANXA11) inhibits cell proliferation, invasion, and migration via the AKT/GSK-3beta pathway in gastric Cancer. Med Sci Monit 24:149–160. https://doi.org/10.12659/msm.905372
doi: 10.12659/msm.905372
pubmed: 29306955
pmcid: 5769363
Roderick HL, Cook SJ (2008) Ca
doi: 10.1038/nrc2374
pubmed: 18432251
Bong AHL, Monteith GR (2018) Calcium signaling and the therapeutic targeting of cancer cells. Biochim Biophys Acta Mol Cell Res 1865:1786–1794. https://doi.org/10.1016/j.bbamcr.2018.05.015 . (11 Pt B))
doi: 10.1016/j.bbamcr.2018.05.015
pubmed: 29842892
He Q, Li Z (2021) The dysregulated expression and functional effect of CaMK2 in cancer. Cancer Cell Int 21(1):326. https://doi.org/10.1186/s12935-021-02030-7
doi: 10.1186/s12935-021-02030-7
pubmed: 34193145
pmcid: 8243487
Subbannayya Y, Syed N, Barbhuiya MA, Raja R, Marimuthu A, Sahasrabuddhe N et al (2015) Calcium calmodulin dependent kinase kinase 2: a novel therapeutic target for gastric adenocarcinoma. Cancer Biol Ther 16(2):336–345. https://doi.org/10.4161/15384047.2014.972264
doi: 10.4161/15384047.2014.972264
pubmed: 25756516
pmcid: 4622549
Brzozowski JS, Skelding KA (2019) The multi-functional calcium/calmodulin stimulated protein kinase (CaMK) family: emerging targets for anti-cancer therapeutic intervention. Pharmaceuticals (Basel) 12(1):8. https://doi.org/10.3390/ph12010008
doi: 10.3390/ph12010008
pubmed: 30621060
Ketterer S, Mitschke J, Ketscher A, Schlimpert M, Reichardt W, Baeuerle N et al (2020) Cathepsin D deficiency in mammary epithelium transiently stalls breast cancer by interference with mTORC1 signaling. Nat Commun 11(1):5133. https://doi.org/10.1038/s41467-020-18935-2
doi: 10.1038/s41467-020-18935-2
pubmed: 33046706
pmcid: 7552405
Rochefort H, Liaudet-Coopman E (1999) Cathepsin D in cancer metastasis: a protease and a ligand. APMIS 107(1):86–95. https://doi.org/10.1111/j.1699-0463.1999.tb01530.x
doi: 10.1111/j.1699-0463.1999.tb01530.x
pubmed: 10190284
He B, Xiao YF, Tang B, Wu YY, Hu CJ, Xie R et al (2016) hTERT mediates gastric cancer metastasis partially through the indirect targeting of ITGB1 by microRNA-29a. Sci Rep 6:21955. https://doi.org/10.1038/srep21955
doi: 10.1038/srep21955
pubmed: 26903137
pmcid: 4763288
Siddiqui N, Sonenberg N (2015) Signalling to eIF4E in cancer. Biochem Soc Trans 43(5):763–772. https://doi.org/10.1042/BST20150126
doi: 10.1042/BST20150126
pubmed: 26517881
pmcid: 4613458
Carroll M, Borden KL (2013) The oncogene eIF4E: using biochemical insights to target cancer. J Interferon Cytokine Res 33(5):227–238. https://doi.org/10.1089/jir.2012.0142
doi: 10.1089/jir.2012.0142
pubmed: 23472659
pmcid: 3653383
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL (2020) ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med 19(3):1997–2007. https://doi.org/10.3892/etm.2020.8454
doi: 10.3892/etm.2020.8454
pubmed: 32104259
pmcid: 7027163
Busca R, Pouyssegur J, Lenormand P (2016) ERK1 and ERK2 map kinases: specific roles or functional redundancy? Front Cell Dev Biol 4:53. https://doi.org/10.3389/fcell.2016.00053
doi: 10.3389/fcell.2016.00053
pubmed: 27376062
pmcid: 4897767
Sun L, Chen G, Sun A, Wang Z, Huang H, Gao Z et al (2020) BAG2 promotes proliferation and metastasis of gastric cancer via ERK1/2 signaling and partially regulated by miR186. Front Oncol 10:31. https://doi.org/10.3389/fonc.2020.00031
doi: 10.3389/fonc.2020.00031
pubmed: 32082999
pmcid: 7005010
Nam S, Kim JH, Lee DH (2019) RHOA in gastric cancer: functional roles and therapeutic potential. Front Genet 10:438. https://doi.org/10.3389/fgene.2019.00438
doi: 10.3389/fgene.2019.00438
pubmed: 31156701
pmcid: 6529512
Gomes C, Osorio H, Pinto MT, Campos D, Oliveira MJ, Reis CA (2013) Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS One 8(6):e66737. https://doi.org/10.1371/journal.pone.0066737
doi: 10.1371/journal.pone.0066737
pubmed: 23799130
pmcid: 3682978
Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH (2012) Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem 287(15):12132–12141. https://doi.org/10.1074/jbc.M111.302299
doi: 10.1074/jbc.M111.302299
pubmed: 22337890
pmcid: 3320958